Rivaroxaban with Aspirin in Stable Cardiovascular Disease: An Observational Study in Indian Patients

Dr Viveka Kumar0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1.Willing and able to provide written informed consent
•2.Age >18 years, either gender and known case stable coronary artery disease (CAD)
•3.Patient at high risk for atherothrombosis
•4.Patient eligible for dual pathway therapy (Rivaroxaban plus Aspirin) based on clinical judgement and receiving the same

•1.Clinically considered high risk of bleeding
•2.Presence of gastrointestinal bleed
•3.Stroke within 1 month or any history of hemorrhagic or lacunar stroke
•4.Severe heart failure with known ejection fraction <30% or New York Heart Association (NYHA) class III or IV symptoms
•5.Estimated glomerular filtration rate (eGFR) <15 mL/min
•6.Clinically requiring dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy
•7.History of hypersensitivity or known contraindication for rivaroxaban, aspirin, or excipients, if applicable.
•8.Systemic treatment with strong inhibitors of both CYP 3A4 and p-glycoprotein (P-gp) (e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus [HIV]-protease inhibitors, such as ritonavir), or strong inducers of CYP 3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin, and carbamazepine.
•9.Subjects who are pregnant, breastfeeding, or are of childbearing potential, and sexually active and not practicing an effective method of birth control

发起方

Dr Viveka Kumar